Cologuard

DEVICE5 trials

Sponsors

Exact Sciences Corporation, University of California, San Diego

Conditions

Colon CancerColorectal CancerColorectal Cancer (CRC)Colorectal Cancer ScreeningFecal Immunochemical TestMulti-target Stool DNA

Unknown Phase

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

CompletedNCT02419716

Exact Sciences CorporationColorectal Cancer, Colorectal Cancer Screening

Start: 2015-04-30End: 2020-03-16Updated: 2020-04-02

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

TerminatedNCT03705013

Exact Sciences CorporationColorectal Cancer

Start: 2018-10-30End: 2019-11-16Updated: 2020-04-14

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

Active, not recruitingNCT04124406

Exact Sciences CorporationColon Cancer

Start: 2019-10-18End: 2025-12-31Target: 150000Updated: 2025-10-03

Head to Head Pilot Trial of Mailed Cologuard to Mailed FIT

Active, not recruitingNCT06173375

University of California, San DiegoColorectal Cancer

Start: 2024-05-15End: 2025-12-31Target: 100Updated: 2025-11-04

Head to Head Trial of Mailed Cologuard to Mailed FIT

Enrolling by invitationNCT06931860

University of California, San DiegoColorectal Cancer (CRC), Colorectal Cancer Screening, Fecal Immunochemical Test +1

Start: 2025-09-05End: 2027-09-30Target: 400Updated: 2025-09-09

Related Papers

Recruitment strategies and consent rates in a national prospective colorectal cancer screening cohort: results from year 1 of the Voyage Study

BMJ Open Gastroenterology2024-07-011 citations

Colorectal cancer outcomes after screening with the multi-target stool DNA assay: protocol for a large-scale, prospective cohort study (the Voyage study)

BMJ Open Gastroenterology2020-02-0112 citations